A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Trial Details

NCT ID
NCT07235293
Phase
PHASE2
Sponsor
Kahr Bio Australia Pty Ltd
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • DSP107 + Atezolizumab
  • Fruquintinib
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Florida City, Florida, United States|25.44789,-80.47922
  • Durham, North Carolina, United States|35.99403,-78.89862
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Texas City, Texas, United States|29.38385,-94.9027

Key Eligibility Criteria

  • Are ≥ 18 years of age with a life expectancy of \> 3 months.
  • Participants with histologically confirmed, inoperable, MSS and/or pMMR CRC which has progressed to, or is intolerant to, specified therapies (and …
  • Note: Lines of therapy are defined by disease progression between therapies. Participants who discontinue their prior regimen due to toxicity (in t…
  • Measurable disease per RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →